ACC 2026
Cholesterol Drug Cuts Cardiac Risk by Nearly a Third in Diabetic Patients, Before Disease Sets in
VESALIUS-CV subanalysis: evolocumab reduces major adverse cardiac events by 31%
Saif Quadri
April 9, 2026
VESALIUS-CV subanalysis: evolocumab reduces major adverse cardiac events by 31%
Phase 2 trial of tonlamarsen in resistant hypertension: the drug’s
STEMI-DTU trial: Delayed reperfusion with LV unloading shows no significant
Long-awaited survival data from the ARTO trial have confirmed that
A prospective single-surgeon series has demonstrated that the Lisbon Zero-Clip
A single-institution study from the University of California, Irvine has
A large prospective multicentre registry study has identified a comprehensive
A multicentre retrospective series from Mexico has reported that radical
A landmark international survey spanning 93 countries and more than
A large, multicentre randomised controlled trial comparing conventional laparoscopic and
The comprehensive study was presented on Monday, September 15th, 2025
The research study was presented on Monday, September 15th, 2025